Personalized Cancer Diagnostics with CNSide™
Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. Through CNSide™, Biocept’s test menu focuses on cancer biomarkers that are clinically actionable based on clinical treatment guidelines listed by the National Comprehensive Cancer Network® (NCCN®).
Using every tool available to deliver the most accurate and complete results, we leverage the right technology for the right test. Learn more about our technology options.
Benefits
CSF-TC Tests
CSF-TCs obtained through our platform can be used to molecularly characterize tumor cells and evaluate changes in protein expression with the same techniques done in tissue.
The same specimen can be analyzed for DNA and protein targets.
All CSF-TC tests are enumerated and can be used in monitoring applications.
Benefits
cfDNA Tests
Performing sequencing delivers added confidence to final result.
NGS technology allows multiplexing capabilities and future panel development.
Complete Platform
CSF-TC PLATFORM
- Translocations
- DNA Amplifications
- Protein Expression
cfDNA PLATFORM
- Single Nucleotide Variants (SNVs)
- Insertions
- Deletions
Partner with Biocept
Contact us to learn how Biocept can support your research and testing.
Contact Mike Terry, Senior Vice President, Corporate Development, for more information at 858.320.8200 Ext. 297 or via email at mterry@biocept.com.